India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
You may also be interested in...
Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.
India's apex court recently dismissed Bayer's plea in the high profile Nexavar (sorafenib tosylate) compulsory licensing litigation, but the case hearing appears yet again to have touched upon the delicate issue of R&D spends along the way.
Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company' capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.